Regulators Revisit Approval Pathway for Plant-Based Therapies
The FDA is conducting a fresh review of botanical drug regulations. This comes alongside coverage of Ionis' first approval for Alexander disease and updates on a major schizophrenia treatment hurdle.
Expanded Detail
EXPANDED:
The FDA's decision to re-examine its regulatory framework for botanical drugs signals a potential shift in how natural compounds are evaluated for medical use. This review aims to clarify the scientific and administrative standards required for plant-based treatments to gain official approval.
This regulatory update appears alongside other significant developments in the pharmaceutical sector, including the first-ever approval for a therapy targeting Alexander disease and a notable setback in the progress
Expanded detail and Context are AI-generated analysis; the linked article remains the authoritative source.
Related stories
FDA approves Ionis' RNA-based treatment for rare Alexander disease · Drug development
AstraZeneca's failed heart trial sparks doubts about silencer drug class · Drug development
UniQure seeks FDA and UK approval for Huntington's gene therapy AMT-130 · Drug development
FDA clears Revolution Medicines' daraxonrasib for pancreatic cancer · Cancer research
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “FDA takes another look at botanical drugs.” Browse more stories.